Aegerion Pharma Cancels Another IPO

Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug company focused on cardiovascular and metabolic diseases, has withdrawn registration for an $86.25 million IPO, due to “market conditions.” This is the second time in as many years that Aegerion has canceled a proposed IPO.

 

It had planned to trade on the Nasdaq, with Piper Jaffray and Thomas Weisel serving as co-lead underwriters. Aegerion has raised around $44 million in total VC funding, from firms like Index Ventures, Advent International, Alta Partners, Scheer & Co. and MVM Life Science Partners. www.aegerion.com

Related Posts

Leave a Reply

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget